Factor 11a Inhibitors vs DOACs: The New Standard in Anticoagulation Therapy? Introduction Venous thromboembolism (VTE) affects nearly 900,000 people annually in the United States, with an estimated 60,000-100,000 individuals dying from related complications. Factor 11a inhibitors represent a promising new frontier in anticoagulation
Tag: Venous thromboembolism
Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin
Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin Check out our extensive video library (see channel for our latest videos) Abstract Antiphospholipid syndrome (APS) represents a complex autoimmune disorder characterized by thrombotic events and pregnancy complications in patients with persistent antiphospholipid antibodies. The traditional anticoagulant
New Anticoagulants vs LMWH in Cancer-Associated Thrombosis: Latest Evidence
New Anticoagulants vs LMWH in Cancer-Associated Thrombosis: Latest Evidence Please like and subscribe if you enjoyed this video :-) Introduction Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains one of the most common and life-threatening complications in patients with cancer.
When Blood Clots Strike Young: What Every Doctor Should Know About VTE in Millennials – Unusual Thrombotic Presentations and Risk Factors
